Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Santarus' 1Q13 earnings beat Street

Santarus Inc. (NASDAQ:SNTS) jumped $2.13 (11%) to $21 in early

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE